Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP2 | O75604 | 1/20 | 0.66 |
| ▸ | CYP3A4 | P08684 | 4/20 | 0.64 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.64 |
| ▸ | NFKB1 | P19838 | 2/20 | 0.64 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.64 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.64 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.64 |
| ▸ | MEN1 | O00255 | 1/20 | 0.64 |
| ▸ | TP53 | P04637 | 1/20 | 0.64 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.64 |
| ▸ | MYLK | Q15746 | 1/20 | 0.64 |
| ▸ | MAPT | P10636 | 3/20 | 0.62 |
| ▸ | LMNA | P02545 | 2/20 | 0.62 |
| ▸ | GMNN | O75496 | 1/20 | 0.62 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.62 |
| ▸ | HTR6 | P50406 | 3/20 | 0.54 |
| ▸ | TSHR | P16473 | 3/20 | 0.52 |
| ▸ | CHRM4 | P08173 | 2/20 | 0.52 |
| ▸ | THPO | P40225 | 1/20 | 0.52 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30610303 | 1.00 | USP2 (0.66) | USP2CYP3A4MAPK1NFKB1KMT2A | |
| SCHEMBL3244492 | 0.94 | CYP3A4 (0.74) | USP2CYP3A4MAPK1NFKB1KMT2A | |
| SCHEMBL2959421 | 0.91 | POLB (0.57) | USP2CYP3A4MAPK1NFKB1KMT2A | |
| SCHEMBL10723724 | 0.87 | CHRM4 (0.64) | CYP3A4MAPK1KMT2ACYP2C9MEN1 | |
| SCHEMBL7450856 | 0.83 | CYP3A4 (0.58) | USP2CYP3A4MAPK1NFKB1KMT2A | |
| SCHEMBL31684034 | 0.81 | TSHR (0.78) | CYP3A4MAPK1KMT2ACYP2C9MEN1 | |
| SCHEMBL4555453 | 0.81 | TSHR (0.78) | CYP3A4MAPK1KMT2ACYP2C9MEN1 | |
| SCHEMBL10037158 | 0.81 | USP2 (0.51) | USP2CYP3A4MAPK1NFKB1KMT2A | |
| SCHEMBL29764343 | 0.81 | CYP3A4 (0.55) | USP2CYP3A4MAPK1NFKB1KMT2A | |
| SCHEMBL5352749 | 0.81 | ALDH1A1 (0.67) | USP2CYP3A4MAPK1NFKB1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 34 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7759339-B2 | Hydroxysteroid dehydrogenase inhibitors | TAKEDA SAN DIEGO, INC. (US) | 2010-07-20 | — | — | US | claimed |
| EP-1866298-A2 | HYDROXYSTEROID DEHYDROGENASE INHIBITORS | Takeda San Diego, Inc. (US) | 2007-12-19 | — | — | EP | claimed |
| WO-2006105127-A2 | HYDROXYSTEROID DEHYDROGENASE INHIBITORS | TAKEDA SAN DIEGO, INC. (US) | 2006-10-05 | — | — | WO | claimed |
| US-20060223829-A1 | Hydroxysteroid dehydrogenase inhibitors | TAKEDA SAN DIEGO, INC. | 2006-10-05 | — | — | US | claimed |
| US-9663537-B2 | Chemokine receptor antagonists and methods of use | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2017-05-30 | — | — | US | disclosed |
| US-20160031908-A1 | CHEMOKINE RECEPTOR ANTAGONISTS AND METHODS OF USE THEREOF | KYOWA HAKKO KOGYO CO., LTD. (JP) | 2016-02-04 | — | — | US | disclosed |
| US-20140371207-A1 | CHEMOKINE RECEPTOR ANTAGONISTS AND METHODS OF USE THEREOF | KYOWA HAKKO KIRIN CO., LTD. (JP) | 2014-12-18 | — | — | US | disclosed |
| US-8653096-B2 | Chemokine receptor antagonists and methods of use thereof | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2014-02-18 | — | — | US | disclosed |
| US-20120046311-A1 | CHEMOKINE RECEPTOR ANTAGONISTS AND METHODS OF USE THEREOF | KYOWA HAKKO KOGYO CO., LTD. (JP) | 2012-02-23 | — | — | US | disclosed |
| US-8058287-B2 | Chemokine receptor antagonists and methods of use therefor | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2011-11-15 | — | — | US | disclosed |
| EP-2286811-A1 | Chemokine receptor antagonists and methods of use thereof | Millennium Pharmaceuticals, Inc. (US) | 2011-02-23 | — | — | EP | disclosed |
| US-7759339-B2 | Hydroxysteroid dehydrogenase inhibitors | TAKEDA SAN DIEGO, INC. (US) | 2010-07-20 | — | — | US | disclosed |
| US-6509346-B2 | Antiinflammatory agents | MILLENNIUM PHARMACEUTICALS, INC. | 2003-01-21 | — | — | US | disclosed |
| US-20020169155-A1 | A nitrogen-ring containing triheterocyclic compound is useful for treating a disease associated with aberrant leukocyte recruitment and/or activation | MILLENNIUM PHARMACEUTICALS, INC. | 2002-11-14 | — | — | US | disclosed |
| US-20020119973-A1 | CHEMOKINE RECEPTOR ANTAGONISTS AND METHODS OF USE THEREFOR | MILLENNIUM PHARMACEUTICALS, INC. | 2002-08-29 | — | — | US | disclosed |
| EP-1204665-A2 | CHEMOKINE RECEPTOR ANTAGONISTS AND METHODS OF USE THEREFOR | Millennium Pharmaceuticals, Inc. (US) | 2002-05-15 | — | — | EP | disclosed |
| US-6329385-B1 | ANTIINFLAMMATORY AGENTS, ANTIARTHRITIC AGENTS, VIRAL DISEASES AND GASTROINTESTINAL DISORDERS | MILLENNIUM PHARMACEUTICALS, INC. | 2001-12-11 | — | — | US | disclosed |
| WO-2001009138-A2 | CHEMOKINE RECEPTOR ANTAGONISTS AND METHODS OF USE THEREFOR | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2001-02-08 | — | — | WO | disclosed |
| EP-1049700-A1 | CHEMOKINE RECEPTOR ANTAGONISTS AND METHODS OF USE THEREFOR | Millennium Pharmaceuticals, Inc. (US) | 2000-11-08 | — | — | EP | disclosed |
| WO-1999037651-A1 | CHEMOKINE RECEPTOR ANTAGONISTS AND METHODS OF USE THEREFOR | MILLENIUM PHARMACEUTICALS, INC. (US) | 1999-07-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020119973-A1 | CHEMOKINE RECEPTOR ANTAGONISTS AND METHODS OF USE THEREFOR | CCL11, ACKR3, CXCR4 | USP2 4039/4885CYP3A4 3471/4885MAPK1 2193/4885 |
| US-20020169155-A1 | A nitrogen-ring containing triheterocyclic compound is useful for treating a disease associated with aberrant leukocyte recruitment and/or activation | NFATC1, ELANE, NCF1 | USP2 2542/4885CYP3A4 4396/4885MAPK1 2140/4885 |
| US-20120046311-A1 | CHEMOKINE RECEPTOR ANTAGONISTS AND METHODS OF USE THEREOF | ACKR3, CCR2, CXCR2 | USP2 4074/4885CYP3A4 4291/4885MAPK1 1826/4885 |
| US-20160031908-A1 | CHEMOKINE RECEPTOR ANTAGONISTS AND METHODS OF USE THEREOF | ACKR3, CCR2, CXCR2 | USP2 4074/4885CYP3A4 4291/4885MAPK1 1826/4885 |
| US-20140371207-A1 | CHEMOKINE RECEPTOR ANTAGONISTS AND METHODS OF USE THEREOF | ACKR3, CCR2, CXCR2 | USP2 4074/4885CYP3A4 4291/4885MAPK1 1826/4885 |
| US-20060223829-A1 | Hydroxysteroid dehydrogenase inhibitors | HSD17B1, HSD17B3, HSD17B2 | USP2 1201/4885CYP3A4 128/4885MAPK1 4198/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.